** Shares of medical device maker Outset Medical OM.O rise 8% to $5.30 premarket
** Co says the U.S. FDA cleared its next-generation dialysis system, Tablo, which has added reliability features
** Adds that Tablo's upgraded cybersecurity meets the FDA's latest standards
** Tablo is used for hemodialysis — a treatment that filters waste from the blood when kidneys fail
** Co says hardware and software updates are aimed at cutting maintenance needs and improving durability in hospitals
** Shipments of the new system to begin in Q2 2026; existing users can upgrade
** Shares fell ~78% in 2025
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))